Published in Nat Rev Neurol on October 27, 2015
Non-motor features of Parkinson disease. Nat Rev Neurosci (2017) 1.42
Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease? Front Neuroanat (2016) 1.39
Adaptive responses of neuronal mitochondria to bioenergetic challenges: Roles in neuroplasticity and disease resistance. Free Radic Biol Med (2016) 0.82
The bowel and beyond: the enteric nervous system in neurological disorders. Nat Rev Gastroenterol Hepatol (2016) 0.80
Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease. Acta Neuropathol Commun (2017) 0.79
Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans. Sci Rep (2016) 0.78
Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease. J Neuroimmune Pharmacol (2016) 0.77
Parkinson's: a syndrome rather than a disease? J Neural Transm (Vienna) (2016) 0.76
Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra. J Neurol (2017) 0.76
Opening up the DNA methylome of dementia. Mol Psychiatry (2017) 0.75
The Effect of Microbiota and the Immune System on the Development and Organization of the Enteric Nervous System. Gastroenterology (2016) 0.75
Weight Change Is a Characteristic Non-Motor Symptom in Drug-Naïve Parkinson's Disease Patients with Non-Tremor Dominant Subtype: A Nation-Wide Observational Study. PLoS One (2016) 0.75
Modeling-Enabled Systems Nutritional Immunology. Front Nutr (2016) 0.75
Pattern of Reduced Functional Connectivity and Structural Abnormalities in Parkinson's Disease: An Exploratory Study. Front Neurol (2017) 0.75
Genetic association of NOS1 exon18, NOS1 exon29, ABCB1 1236C/T, and ABCB1 3435C/T polymorphisms with the risk of Parkinson's disease: A meta-analysis. Medicine (Baltimore) (2016) 0.75
Changes in the sympathetic innervation of the gut in rotenone treated mice as possible early biomarker for Parkinson's disease. Clin Auton Res (2016) 0.75
Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff. J Parkinsons Dis (2017) 0.75
Parkinson's disease as a multisystem disorder. J Neural Transm (Vienna) (2017) 0.75
Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. F1000Res (2017) 0.75
The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials. Neurol Sci (2016) 0.75
Pink1 interacts with α-synuclein and abrogates α-synuclein-induced neurotoxicity by activating autophagy. Cell Death Dis (2017) 0.75
Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis. Int J Mol Sci (2017) 0.75
Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed. J Neural Transm (Vienna) (2017) 0.75
Microtubule Destabilization Paves the Way to Parkinson's Disease. Mol Neurobiol (2016) 0.75
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
The functional anatomy of basal ganglia disorders. Trends Neurosci (1989) 12.28
Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci (2000) 10.62
Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res (2004) 7.06
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Oxidative stress in Parkinson's disease. Ann Neurol (2003) 5.93
Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol (2006) 5.40
Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci (2012) 4.95
Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol (2015) 4.94
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A (2011) 4.91
Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol (2006) 4.72
Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord (2014) 3.97
Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect (2011) 3.87
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord (2009) 3.56
Frequency of bowel movements and the future risk of Parkinson's disease. Neurology (2001) 3.50
Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett (2005) 3.30
International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord (2006) 3.13
Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol (2001) 3.09
Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol (2003) 2.85
Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol (2008) 2.78
Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) (2003) 2.75
Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (2010) 2.73
Toxin-induced models of Parkinson's disease. NeuroRx (2005) 2.67
Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol (2008) 2.58
Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology (1992) 2.57
Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci (2008) 2.51
Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol (2002) 2.46
Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord (2004) 2.41
The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol (2007) 2.38
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis (2011) 2.32
The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology (1998) 2.32
The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord (2011) 2.24
Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun (1989) 2.23
How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord (2000) 2.23
Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol (2003) 2.19
Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One (2010) 2.15
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener (2012) 2.11
Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology (1984) 2.08
Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol (2007) 2.08
Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol (1988) 2.01
Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res (2001) 2.01
Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology (1996) 2.01
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem (2001) 1.99
Patient-reported autonomic symptoms in Parkinson disease. Neurology (2007) 1.93
Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep (2014) 1.90
Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol (2006) 1.87
Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol (2010) 1.86
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord (2007) 1.85
Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol (1994) 1.84
Well-water consumption and Parkinson's disease in rural California. Environ Health Perspect (2009) 1.81
What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord (2010) 1.80
TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem (2002) 1.77
Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol (1990) 1.76
Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease. Parkinsonism Relat Disord (2013) 1.74
Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm (Vienna) (2004) 1.74
Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One (2010) 1.72
Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology (1992) 1.71
Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry (1991) 1.69
Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology (2009) 1.64
The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord (2013) 1.62
Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology (1987) 1.61
Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci (2003) 1.58
The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease. Neuropathol Appl Neurobiol (2008) 1.58
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci (1999) 1.58
Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet (1995) 1.57
Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol (2007) 1.56
Enteric GFAP expression and phosphorylation in Parkinson's disease. J Neurochem (2014) 1.51
Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol (2004) 1.49
Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol (2008) 1.46
Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol (2009) 1.45
Gastrointestinal symptoms in Parkinson's disease. Mov Disord (1991) 1.44
The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord (2003) 1.44
Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One (2011) 1.40
Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep (2012) 1.36
Gastrointestinal dysfunction in Parkinson's Disease. J Neurol Sci (2009) 1.35
Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J Neurol (2003) 1.35
Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem (2007) 1.34
Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study. Neurology (2007) 1.34
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol (2013) 1.34
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Cigarette smoking and Parkinson's disease. Neurology (1986) 1.33
Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology (2008) 1.32
Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology (2005) 1.31
Pathological lesions in colonic biopsies during Parkinson's disease. Gut (2008) 1.29
The role of glial cells and apoptosis of enteric neurones in the neuropathology of intractable slow transit constipation. Gut (2005) 1.29
Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study. Acta Neuropathol (2003) 1.29
Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. J Cell Biol (2011) 1.28
Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat Disord (2010) 1.27
Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord (2007) 1.25
Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord (2008) 1.24
Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases. Acta Neuropathol (1984) 1.23
Voices from within: gut microbes and the CNS. Cell Mol Life Sci (2012) 1.21
Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol (2005) 1.21
Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J Neural Transm (Vienna) (1996) 1.20
Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration. Biochem Soc Trans (2005) 1.20